AUPH — Aurinia Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1600620 ·
Last close
$16.57
Market Cap
$2.20B
52W High
$19.25
52W Low
$14.36
ADV30
1,142,202
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 83,220,000 | 76,665,000 | 46,341,000 | 37,414,000 | 792,262,000 | 179,832,000 | 177,398,000 |
| Mar 2026 | 77,705,000 | 71,200,000 | 41,422,000 | 34,355,000 | 723,997,000 | 41,008,000 | 156,371,000 |
| Dec 2025 | 77,114,000 | 68,315,000 | 33,239,000 | 210,794,000 | 751,587,000 | 80,213,000 | 170,256,000 |
| Sep 2025 | 73,468,000 | 65,291,000 | 29,745,000 | 31,551,000 | 527,528,000 | 73,189,000 | 161,757,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$166,918,000
Investing CF
$-81,880,000
Financing CF
$-110,458,000
CapEx
$-274,000
Dividends Paid
—
Buybacks
$-87,400,000
EPS Diluted TTM
$2.17
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-615,013,000
Inventory
$46,410,000
Receivables
$49,175,000
ST Investments
$337,775,000
EBIT TTM
$138,008,000
Pretax Income TTM
$133,733,000
Interest Exp TTM
$4,275,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$311,507,008
EBITDA
$179,826,000
Free Cash Flow
$147,817,120
Enterprise Value
$1,836,414,976
Total Cash
$443,023,008
Total Debt
$64,136,000
Shares Out
133,051,168
Trailing EPS
$2.28
Book Value
$4.63
ROE
66.1%
ROA
15.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 283,055,000 | 106,561,000 | 287,202,000 | 751,587,000 | 170,256,000 | — | 135,658,000 |
| Dec 2024 | 235,133,000 | 18,419,000 | 5,752,000 | 550,645,000 | 173,167,000 | — | 44,388,000 |
| Dec 2023 | 175,513,000 | -91,691,000 | -78,020,000 | 548,062,000 | 170,108,000 | — | -33,461,000 |
| Dec 2022 | 134,030,000 | -111,470,000 | -108,180,000 | 470,860,000 | 65,425,000 | — | -79,529,000 |
TTM Snapshot
Revenues TTM
$178,065,000
NetIncome TTM
$-8,086,000
OpCashFlow TTM
$0
Assets (Latest)
$550,645,000
Forward EPS
$1.07
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $30.00 · spot: $16.57 · call volume: 157 · put volume: 236
Expected Move to 2027-01-15:
±$3.60
(21.73%) —
implied range
$12.97 –
$20.17
· ATM straddle on $17.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | $2.23B | $25.27 | — |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.24B | $38.50 | — |
| XNCR | Xencor Inc | $2.16B | $29.00 | — |
| URGN | UroGen Pharma Ltd. | $2.26B | $46.16 | — |
| KLRA | Kailera Therapeutics, Inc. | $2.14B | $16.54 | — |
News headlines (Yahoo Finance, 1h cache)
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback
2026-08-20 07:11 · Yahoo
Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now?
2026-06-29 20:07 · Yahoo
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
2026-06-23 11:08 · Yahoo
Aurinia Pharmaceuticals and Four More Stocks See Activist Action
2026-06-12 22:47 · Yahoo
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
2026-06-07 12:17 · Yahoo
AUPH Stock Rallies 6% After-Hours — Here’s Why
2026-08-19 22:15 · Yahoo
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
2026-07-06 12:00 · Yahoo
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
2026-06-04 11:00 · Yahoo
Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain
2026-08-20 00:16 · Yahoo
Aurinia Settles Patent Litigation with Teva
2026-08-19 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.